Dr. Lorin K. Roskos Appointed Chief Scientific Officer and Head of Quantitative Clinical Pharmacology

Pleasanton, California – 17 September 2025 – Crystal Bio Solutions (CBS), a wholly owned subsidiary of Crystal Pharmatech, today announced an exciting expansion of its services with the launch of Quantitative Clinical Pharmacology (QCP) and the appointment of Dr. Lorin K. Roskos as Chief Scientific Officer and Head of Quantitative Clinical Pharmacology.

Dr. Roskos brings more than 30 years of leadership experience in pharmaceutical R&D. He has held senior positions at Amgen, AstraZeneca, and Exelixis, and is internationally recognized for his expertise in translational science, clinical pharmacology, and bioanalysis. His work spans across oncology, autoimmune, respiratory, cardiovascular, renal, metabolic, and infectious diseases. Over his career, he has published more than 100 research papers and reviews and contributed to numerous successful drug approvals worldwide.

From Preclinical to Market

With the addition of QCP, CBS is evolving from a large-molecule analytical CRO into a clinical development science partner, providing internationally compliant services in CMC analytics, bioanalysis, biomarker development, and quantitative clinical pharmacology.

These capabilities extend seamlessly from preclinical research through market launch. Backed by unified technology platforms, quality systems, and global management standards, our mission is clear: to help pharma and biotech companies worldwide improve efficiency and increase success rates.

Quantitative Clinical Pharmacology Services

The new QCP division will provide targeted support for clinical development, including:

• Population PK/PD modeling

• Exposure–response analysis for clinical endpoints

• Dose optimization and clinical trial design

• Covariate analysis for PK, efficacy, and safety

• Biostatistics support, including SAS programming and non-compartmental analysis (NCA)

With advanced modeling and simulation expertise, CBS accelerates drug development across a wide range of modalities, including novel and emerging therapies.

End-to-End Drug Development Solutions

“CBS’s expansion into QCP reflects our commitment to provide highly specialized scientific support” said Dr. Alex Chen, CEO of CBS and Crystal Pharmatech. “It marks a key milestone in our evolution, strengthening our role as a trusted scientific partner and technical consultant to the industry." After 15 years of excellent service provided towards small molecule drug developers, Alex and Crystal Pharmatech are ready for the next chapter. "By integrating quantitative clinical pharmacology, bioanalysis, and CMC capabilities, we are building an advanced decision-support system that covers the full drug development cycle. Leveraging Crystal Pharmatech’s leadership in small-molecule crystalization and formulation, we bring cross-technology advantages to biologics and innovative therapies, helping projects worldwide overcome complex development challenges, reduce uncertainty, and deliver high-quality therapies to patients faster.”